Phase II Trial of Stereotactic Radiosurgery Boost Following Surgical Resection for Brain Metastases

PHASE2CompletedINTERVENTIONAL
Enrollment

51

Participants

Timeline

Start Date

June 30, 2004

Primary Completion Date

January 31, 2009

Study Completion Date

January 31, 2009

Conditions
Brain MetastasisBladder CancerBreast CancerCervical CancerColon CancerHEENT CancerLung CancerMelanomaPancreatic CancerProstate CancerRectal CancerSarcomaTesticular Cancer
Interventions
RADIATION

Stereotactic Radiosurgery

"All patients would undergo craniotomy and the goal of surgery in all cases would be total removal of the metastases. The patient will initially receive premedication with 0.5- 1mg of Ativan orally prior to SRS procedure. Subsequently, the patient will have the stereotactic head ring placement under local anesthesia. A peripheral IV will be placed for administration of the intravenous contrast. Thin-section CT images will be obtained with intravenous contrast with head ring in place for the purpose of treatment planning.~A fusion program will be used to combine the recently obtained MRI images along with the CT scans. The target volume as well as the critical structures will be contoured. SRS would be delivered using either the Brain Lab or Radionics Radiosurgery planning and delivery system. Patients would receive a single treatment ranging from 15-22 GY."

Trial Locations (1)

10065

Memorial Sloan-Kettering Cancer Center, New York

All Listed Sponsors
lead

Memorial Sloan Kettering Cancer Center

OTHER

NCT00587964 - Phase II Trial of Stereotactic Radiosurgery Boost Following Surgical Resection for Brain Metastases | Biotech Hunter | Biotech Hunter